Published in Ann Rheum Dis on April 01, 2010
Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis (OPTIWIT) | NCT02770794
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis (2015) 2.53
Biologic discontinuation studies: a systematic review of methods. Ann Rheum Dis (2013) 2.42
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management. Arch Intern Med (2011) 1.43
Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis (2013) 1.19
The Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol (2010) 1.07
Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskelet Disord (2013) 1.03
Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis (2015) 0.99
Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther (2013) 0.98
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial. Ann Rheum Dis (2014) 0.98
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford) (2014) 0.91
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int (2013) 0.91
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis (2013) 0.90
The value of early intervention in RA--a window of opportunity. Clin Rheumatol (2011) 0.89
Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Rheumatology (Oxford) (2014) 0.89
Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. Drugs (2014) 0.88
Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. Arthritis Res Ther (2013) 0.87
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis (2015) 0.86
Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int (2011) 0.86
Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther (2015) 0.85
Biologicals in rheumatoid arthritis: current and future. RMD Open (2015) 0.84
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskelet Disord (2012) 0.84
Current concepts in the management of rheumatoid arthritis. Korean J Intern Med (2016) 0.84
A New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP? Front Immunol (2012) 0.83
Combination with methotrexate and cyclophosphamide attenuated maturation of dendritic cells: inducing Treg skewing and Th17 suppression in vivo. Clin Dev Immunol (2013) 0.80
Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. Rheumatol Int (2013) 0.80
Combination treatment with fingolimod and a pathogenic antigen prevents relapse of glucose-6-phosphate isomerase peptide-induced arthritis. Immun Inflamm Dis (2016) 0.79
Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis. Clin Rheumatol (2012) 0.78
Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study. Arthritis Res Ther (2011) 0.78
bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatol Ther (2017) 0.77
Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases. Clin Rheumatol (2014) 0.77
The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Am J Gastroenterol (2016) 0.77
Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients' opinion. Clin Rheumatol (2014) 0.75
Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Rheumatology (Oxford) (2015) 0.75
Little evidence for prediction of successful dose reduction or discontinuation of a biologic in rheumatoid arthritis: A systematic review. Arthritis Rheumatol (2016) 0.75
Are we on our way to change our mode of thinking and treating inflammatory bowel disease patients? Ann Gastroenterol (2014) 0.75
Therapy: Challenging the course of RA: time for drug-free remission? Nat Rev Rheumatol (2010) 0.75
Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up. Rheumatol Int (2017) 0.75
[Treatment reduction in well-controlled rheumatoid arthritis. State of knowledge]. Z Rheumatol (2015) 0.75
Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother (2014) 0.75
Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol (2016) 0.75
Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study. Clin Rheumatol (2017) 0.75
[Rheumatoid arthritis]. Z Rheumatol (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med (2007) 5.05
Rheumatoid arthritis. Lancet (2009) 4.69
How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol (2000) 4.31
Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis (1992) 2.26
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum (2008) 2.07
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis (2007) 2.01
Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. Arthritis Rheum (2007) 1.90
DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis (2010) 1.87
Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis (2008) 1.36
Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol (2008) 1.34
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). Mod Rheumatol (2008) 1.29
Proposed [corrected] Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol (2005) 1.28
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol (2007) 1.25
Radiographic progression in rheumatoid arthritis: does it reflect outcome? Does it reflect treatment? Ann Rheum Dis (2001) 1.07
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol (2008) 1.02
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum (1999) 7.67
Imaging of single fluorescent molecules and individual ATP turnovers by single myosin molecules in aqueous solution. Nature (1995) 7.62
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res (1998) 6.42
Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci (1995) 6.36
E-CELL: software environment for whole-cell simulation. Bioinformatics (1999) 6.29
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 5.17
The structure of mammalian small nuclear ribonucleoproteins. Identification of multiple protein components reactive with anti-(U1)ribonucleoprotein and anti-Sm autoantibodies. J Biol Chem (1984) 4.68
Mechanism of interaction between Ku protein and DNA. J Biol Chem (1986) 4.22
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature (1998) 3.86
A mutation in the insulin 2 gene induces diabetes with severe pancreatic beta-cell dysfunction in the Mody mouse. J Clin Invest (1999) 3.86
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77
New antibiotics, bleomycin A and B. J Antibiot (Tokyo) (1966) 3.58
The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature (1991) 3.48
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood (1999) 3.46
Mini-laparoscopic appendectomy using a needle loop retractor offers optimal cosmetic results. Surg Endosc (2004) 3.38
Electric-field-induced superconductivity in an insulator. Nat Mater (2008) 3.17
Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene (2007) 3.11
Editorial: The First Specialist Qualification Examination of the Japanese Society of Intravascular Neurosurgery (JSIN). Interv Neuroradiol (2004) 3.03
A high-speed atomic force microscope for studying biological macromolecules. Proc Natl Acad Sci U S A (2001) 2.97
Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet (1990) 2.87
Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol (1996) 2.83
Autoantibodies to the U2 small nuclear ribonucleoprotein in a patient with scleroderma-polymyositis overlap syndrome. J Biol Chem (1984) 2.81
Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J Biol Chem (1986) 2.79
Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat Genet (2001) 2.79
Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest (1981) 2.68
Single molecule imaging of fluorophores and enzymatic reactions achieved by objective-type total internal reflection fluorescence microscopy. Biochem Biophys Res Commun (1997) 2.65
Migrastatin, a new inhibitor of tumor cell migration from Streptomyces sp. MK929-43F1. Taxonomy, fermentation, isolation and biological activities. J Antibiot (Tokyo) (2000) 2.64
RecQ DNA helicase is a suppressor of illegitimate recombination in Escherichia coli. Proc Natl Acad Sci U S A (1997) 2.51
Ludloff's medial approach for open reduction of congenital dislocation of the hip. A 20-year follow-up. J Bone Joint Surg Br (1996) 2.45
Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol (1984) 2.43
Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: A study using mice lacking TNF-alpha. Circulation (2001) 2.36
CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry (2009) 2.36
Essential role for Gab2 in the allergic response. Nature (2001) 2.32
A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med (1993) 2.29
Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum (2001) 2.28
Chemical components in the cell wall of Salmonella typhimurium affecting its virulence and immunogenicity in mice. Nature (1969) 2.22
Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) (2004) 2.19
Disruption of the Bcl6 gene results in an impaired germinal center formation. J Exp Med (1997) 2.17
Crossed aphasia elicited by direct cortical stimulation. Neurology (2006) 2.15
Conserved cysteine to serine mutation in tyrosinase is responsible for the classical albino mutation in laboratory mice. Nucleic Acids Res (1990) 2.13
Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis (2008) 2.11
The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum (1983) 2.09
Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain (1992) 2.09
The roles of three functional sulphate transporters involved in uptake and translocation of sulphate in Arabidopsis thaliana. Plant J (2000) 2.09
Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival. J Biol Chem (1993) 2.07
Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut (2000) 2.06
Fetal Minamata disease. A neuropathological study of two cases of intrauterine intoxication by a methyl mercury compound. J Neuropathol Exp Neurol (1965) 2.05
Isolation of a novel mouse gene MA-3 that is induced upon programmed cell death. Gene (1995) 2.05
Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther (2014) 2.03
DNA-dependent protein kinase (Ku protein-p350 complex) assembles on double-stranded DNA. Proc Natl Acad Sci U S A (1994) 2.01
Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther (2015) 2.01
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis (2007) 2.01
Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med (1999) 1.95
Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci (1987) 1.94
Specificity of mouse hybridoma antibodies to DNA. Immunol Lett (1982) 1.93
Antibodies cross-reactive with DNA and cardiolipin in patients with systemic lupus erythematosus. Clin Exp Immunol (1982) 1.90
Discovery of superconductivity in KTaO₃ by electrostatic carrier doping. Nat Nanotechnol (2011) 1.89
Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg (1994) 1.87
Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol (1986) 1.87
Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes (1987) 1.86
Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. J Clin Invest (1995) 1.85
Identification of bipotential progenitor cells in human liver development. Hepatology (1996) 1.84
Reversal of long-term potentiation (depotentiation) induced by tetanus stimulation of the input to CA1 neurons of guinea pig hippocampal slices. Brain Res (1991) 1.81
Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol (1984) 1.81
Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum (1996) 1.78
Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol (1996) 1.76
Effect of pepstatin on acid proteases. J Antibiot (Tokyo) (1971) 1.75
Ku polypeptides synthesized in vitro assemble into complexes which recognize ends of double-stranded DNA. J Biol Chem (1992) 1.75
Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med (1994) 1.74
Endoscopic submucosal dissection: a safe technique for colorectal tumors. Endoscopy (2007) 1.71
Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res (2001) 1.70
Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem (2001) 1.69
The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys (1996) 1.68
Interleukin-6 is a useful marker for early prediction of the severity of acute pancreatitis. Pancreas (1997) 1.68
Pathological changes observed in the finger biopsy of patients with vibration-induced white finger. Scand J Work Environ Health (1986) 1.67
Regulation of sulfur assimilation in higher plants: a sulfate transporter induced in sulfate-starved roots plays a central role in Arabidopsis thaliana. Proc Natl Acad Sci U S A (1997) 1.67
Nestin expression in the kidney with an obstructed ureter. Kidney Int (2007) 1.66
Post-embryonic expression of C. elegans microRNAs belonging to the lin-4 and let-7 families in the hypodermis and the reproductive system. Dev Dyn (2005) 1.66
Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia (1997) 1.66
Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) (1976) 1.66
Natural history of intracranial cavernous malformations. J Neurosurg (1995) 1.64
Immunocytochemical localization of glutamic acid decarboxylase in neuronal somata following colchicine inhibition of axonal transport. Brain Res (1978) 1.64
An outbreak of visceral larva migrans due to Ascaris suum in Kyushu, Japan. Lancet (1996) 1.62
Melanin production in cultured albino melanocytes transfected with mouse tyrosinase cDNA. Jpn J Genet (1989) 1.61
High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol (2003) 1.61
Variation of the mexT gene, a regulator of the MexEF-oprN efflux pump expression in wild-type strains of Pseudomonas aeruginosa. FEMS Microbiol Lett (2000) 1.60
Gastrointestinal stromal tumors and KIT-positive mesenchymal cells in the omentum. Pathol Int (2001) 1.59
Mediastinal lymph node metastasis in patients with clinical stage I peripheral non-small-cell lung cancer. J Thorac Cardiovasc Surg (1997) 1.59
Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) (1999) 1.57
Unilateral adrenalectomy improves insulin resistance and polycystic ovaries in a middle-aged woman with virilizing adrenocortical adenoma complicated with Cushing's syndrome. J Endocrinol Invest (2007) 1.57
Ischemic stroke and the gene for angiotensin-converting enzyme in Japanese hypertensives. Circulation (1996) 1.57
Simultaneous detection of several Fusarium mycotoxins in cereals, grains, and foodstuffs. J Assoc Off Anal Chem (1981) 1.57
The effect of epidural saline injection on analgesic level during combined spinal and epidural anesthesia assessed clinically and myelographically. Anesth Analg (1997) 1.57
Commonly deleted regions on the long arm of chromosome 21 in differentiated adenocarcinoma of the stomach. Genes Chromosomes Cancer (1997) 1.56
Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients. Am J Surg Pathol (1999) 1.55
Melanization in albino mice transformed by introducing cloned mouse tyrosinase gene. Development (1990) 1.55